{"seq": 1, "variant": "treatment", "cmd": "pm collect FES PET imaging lobular breast cancer --max 200", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41319353\", \"title\": \"Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.\", \"authors\": [\"Covington Matthew F\", \"Salmon Samantha\", \"Kozlov Andrew\", \"Archibald Zane\", \"Butterfield Regan\", \"Stolk Sophie\", \"Mitchell Sam\", \"Boucher Kenneth\", \"Rosenthal Regina\", \"Porretta Jane\", \"Brownson Kirstyn E\", \"Matsen Cindy\", \"Wei Mei\", \"Buys Saundra\", \"Vaklavas Christos\", \"Chittoria Namita\", \"Buckway Brandon\", \"Meite Angela\", \"Yap Jeffrey\"], \"journal\": \"Clinical breast cancer\", \"year\": \"2026\", \"date\": \"2026-01\", \"abstract\": \"Invasive lobular carcinoma (ILC) often presents diagnostic challenges on conventional imaging, necessitating advanced imaging strategies for accurate staging. [18F]Fluoroestradiol (FES), a PET radiopharmaceutical, targets estrogen receptor-positive (ER+) lesions, which are prevalent in ILC. This study evaluates the utility of FES-PET/CT compared to standard-of-care (SOC) imaging for staging ER+ ILC. This IRB-approved prospective trial (October 2022-October 2024) enrolled adults with histologically confirmed ER+ ILC at a National Cancer Institute-designated Comprehensive Cancer Center. Participants underwent FES-PET/CT, with optional [18F]Fluorodeoxyglucose (FDG)-PET/CT. The primary endpoint was the percentage of stage changes post-FES-PET/CT compared to SOC imaging, analyzed using a 1-sided binomial proportions test. Imaging was interpreted by a blinded nuclear and breast radiology specialist, with staging per AJCC eighth edition guidelines. Of 27 enrolled participants, 25 underwent FES-PET/CT (2 excluded due to synthesis failure). Mean age was 60.3 years. Pre-FES-PET/CT staging was stage I (16%), II (60%), III (20%), and IV (4%). FES-PET/CT altered clinical staging in 32% of cases (P = .036), identifying occult stage IV disease in 12.5% and histologically confirmed axillary lymph node metastases in 8%. However, it missed axillary metastases in 28% compared to surgical staging. FDG-PET/CT, performed in 15 participants, showed 40% discordance ", "stderr": "", "elapsed_s": 1.331, "ts": 1771593255.392928}
{"seq": 2, "variant": "treatment", "cmd": "pm collect FES-PET lobular carcinoma --max 200", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41319353\", \"title\": \"Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.\", \"authors\": [\"Covington Matthew F\", \"Salmon Samantha\", \"Kozlov Andrew\", \"Archibald Zane\", \"Butterfield Regan\", \"Stolk Sophie\", \"Mitchell Sam\", \"Boucher Kenneth\", \"Rosenthal Regina\", \"Porretta Jane\", \"Brownson Kirstyn E\", \"Matsen Cindy\", \"Wei Mei\", \"Buys Saundra\", \"Vaklavas Christos\", \"Chittoria Namita\", \"Buckway Brandon\", \"Meite Angela\", \"Yap Jeffrey\"], \"journal\": \"Clinical breast cancer\", \"year\": \"2026\", \"date\": \"2026-01\", \"abstract\": \"Invasive lobular carcinoma (ILC) often presents diagnostic challenges on conventional imaging, necessitating advanced imaging strategies for accurate staging. [18F]Fluoroestradiol (FES), a PET radiopharmaceutical, targets estrogen receptor-positive (ER+) lesions, which are prevalent in ILC. This study evaluates the utility of FES-PET/CT compared to standard-of-care (SOC) imaging for staging ER+ ILC. This IRB-approved prospective trial (October 2022-October 2024) enrolled adults with histologically confirmed ER+ ILC at a National Cancer Institute-designated Comprehensive Cancer Center. Participants underwent FES-PET/CT, with optional [18F]Fluorodeoxyglucose (FDG)-PET/CT. The primary endpoint was the percentage of stage changes post-FES-PET/CT compared to SOC imaging, analyzed using a 1-sided binomial proportions test. Imaging was interpreted by a blinded nuclear and breast radiology specialist, with staging per AJCC eighth edition guidelines. Of 27 enrolled participants, 25 underwent FES-PET/CT (2 excluded due to synthesis failure). Mean age was 60.3 years. Pre-FES-PET/CT staging was stage I (16%), II (60%), III (20%), and IV (4%). FES-PET/CT altered clinical staging in 32% of cases (P = .036), identifying occult stage IV disease in 12.5% and histologically confirmed axillary lymph node metastases in 8%. However, it missed axillary metastases in 28% compared to surgical staging. FDG-PET/CT, performed in 15 participants, showed 40% discordance ", "stderr": "", "elapsed_s": 1.334, "ts": 1771593273.1585958}
